TOPLINE:

Adding a designated pharmacist to hematology-oncology teams reduced adverse drug reaction (ADR) rates by 62% (age-adjusted hazard ratio [AHR], 0.38). The pharmacist made 588 recommendations with a 95% implementation rate, identifying 287 medication errors.

METHODOLOGY:

A parallel randomized clinical trial conducted from July 2020 to October 2022 included 182 patients randomly assigned in a 1:1 ratio to receive comprehensive pharmacist intervention or standard care.

Participants were monitored over a 4-month intervention period and 1 month afterward, with the pharmacist evaluating treatments, providing medication counseling, and making recommendations to physicians in the intervention group.

Research took place in the hematology-oncology unit of a medical center owned by Clali

See Full Page